Valeant Pharmaceuticals

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Gilead ordered to pay $200m to Merck in patent row

Pharmalot By Ed Silverman

Dying has become more expensive for some thanks to a Valeant price hike

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant doubled price on assisted-suicide drug

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: AstraZeneca suffers setback with its blood thinner

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant looking to win leniency from feds

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Johnson & Johnson to pay $498M over hip implant injuries

Pharmalot By Ed Silverman

Valeant slashes financial outlook; investors flee ‘a broken company’

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant cuts financial guidance

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: AstraZeneca reworks executive pay and revenue goals

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Valeant CEO insists ‘no other big shoe’ will drop

Pharmalot By Ed Silverman

Lawmakers accuse Valeant of stonewalling their investigation

Pharmalot By Ed Silverman

Why, in the age of Martin Shkreli, patients are still happy with pharma companies

Pharmalot By Ed Silverman

Specialty pharmacy tied to Valeant probed by Arizona regulators

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: VA will provide hepatitis C drugs to all vets

Pharmalot By Ed Silverman

New Valeant board members raise concerns, analyst says

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Insurers investigated over hep C drug coverage, Valeant exec resigns

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Drug makers accused of misleading medical journal on blood thinner

Pharmalot By Ed Silverman

Already facing investor concerns, Valeant hit with another SEC probe

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Glaxo searching for new CEO, Valeant CEO returns from illness

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Some investors losing confidence in Valeant, Sanofi abandoning allergy med